“Several solutions to the problem of discontinuous access to pharmacotherapy are being developed in the form of new, long-acting drug-delivery systems, which gradually release medication over a period of several days or weeks with a single application.” – Siegel, Psychiatry (Edgmont). 2005; 2: 22-31
Like a tailored suit, some things just fit well. This is true in pharmaceuticals. Drugs with certain characteristics are often a good fit for specific conditions and diseases. For example, extended-release parenteral drugs have many benefits, which make them good candidates for psychiatric conditions and chronic pain.
Extended-release parenteral drugs are good candidates for the treatment of psychiatric conditions due to their many benefits. According to a 2005 study, such benefits include better safety and efficacy than immediate-release medications. A 2010 article states that parenteral antipsychotic drugs have been used in Europe for more than 40 years, but they are less common in the United States.
Extended-release parenteral drugs are also good candidates for the treatment of chronic pain. A 2016 article writes, “Overall, pain management guidelines advise the use of extended-release (ER) formulations, rather than immediate-release (IR) formulation because they provide sustained analgesia.” It also notes that the dosing schedule of extended-release formulations is simpler than that of immediate-release formulations and can help prevent opioid abuse.
The benefits of extended-release parenteral drugs make them good candidates for psychiatric conditions and chronic pain. Orbis Biosciences® uses Precision Particle FabricationTM technology to develop extended-release parenteral drugs. Orbis Biosciences knows that all patients deserve the best-fitting medications for their situations.